MSB 0.54% 92.0¢ mesoblast limited

As the gyrating soup of chemotactic antigenic immunocircus...

  1. 1,846 Posts.
    lightbulb Created with Sketch. 199
    As the gyrating soup of chemotactic antigenic immunocircus converges on the insignificant hand wound I incurred in the field today at work,
    my mind is distracted and wends it's way wistfully t'ward page 34 of

    SOPP 8401: Administrative Processing of Original Biologics License
    Applications (BLA) and New Drug Applications (NDA)
    Version: 18
    Effective Date: January 8, 2024


    wherein I reflect on the procedural excitement no doubt enjoyed by a select few at CBER
    in whose hands critical science filters through to the madding crowd cupped broiling and roiling
    in the unseeing hands of inexorable natural selection and it's forces we seek to tame and direct
    as we strive to science the hell out of this mortal coil.

    esp. to wit, Step 154.

    Truely, we need to open a book on the BLA response date - for mine, $5 on 10/10/2024.


    LINK (pdf download)

    149. Perform a quality control review of the CBER generated documents related to the
    application, ensuring that all documents are in the CER, dates are correct, and
    documents are properly signed; the electronic Action Package (eAP) can be used as a
    resource. [RPM]
    150. Send the final draft Approval Letter to all appropriate Review Offices, Branch Chiefs, and
    Division Directors for review and agreement. [RPM, Chair]
    151. Review and comment or concur on Approval Letter. [appropriate review offices,
    Branch Chiefs, and Division Directors]
    152. Send the Approval letter, SBRA and transmittal memo (T 910.01: Transmittal Memo) for
    signature. [RPM] Note: a link to the eAP may be included for Office Director’s reference
    and review during the sign-off process.
    153. Sign the Transmittal Memo, SBRA and Approval Letter. [Office Director(s)]
    a. Signatory Authority for SBRA and Approval Letter
    i. Original BLAs (for existing U.S. License Number)/NDAs:
    a) Office Director or Deputy Office Director, product office
    ii. Original BLAs (for new U.S. License Number)
    a) Office Director or Deputy Office Director, product office AND
    b) Office Director or Deputy Office Director, OCBQ
    154. Issue the Approval Letter and communicate the approval to the applicant. [Chair, RPM]

    https://hotcopper.com.au/data/attachments/6387/6387900-7aad427a423f5a7edd75509a59cd8460.jpg


 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
92.0¢
Change
-0.005(0.54%)
Mkt cap ! $1.050B
Open High Low Value Volume
92.0¢ 92.5¢ 91.5¢ $1.133M 1.233M

Buyers (Bids)

No. Vol. Price($)
13 151980 91.5¢
 

Sellers (Offers)

Price($) Vol. No.
92.0¢ 29989 2
View Market Depth
Last trade - 16.10pm 18/09/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.